By Fineline Cube 
Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its controlling shareholder, ShengBang Yinghao, has signed a Share Transfer Agreement with China National Biotec Group (CNBG). The agreement involves the transfer of ShengBang Yinghao’s total holding of 21.03% of Pacific Shuanglin’s shares to CNBG.
Transaction Details
The total transfer price for the shares is approximately RMB 4.699 billion, with a per-share transfer price of approximately RMB 23.51. The entire consideration will be paid in cash.
Change of Control
Upon completion of the transfer, Pacific Shuanglin’s controlling shareholder will change from ShengBang Yinghao to CNBG. The actual controller will shift from the Shaanxi Provincial People’s Government State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group Co., Ltd. (Sinopharm).
Company Background and Future Impact
Pacific Shuanglin, formerly known as Yichun Engineering Machinery Co., Ltd., was officially renamed on March 30, 2021. The company focuses on the research, development, and sale of blood products. Post-acquisition, CNBG’s share of controlled plasma resources in China will exceed 30%, and it will hold 9 blood product licenses.-Fineline Info & Tech